UPCOMING SESSIONS in ET
Fri, Nov 20, 2026
6:00 – 7:00 AM Bangkok
Sadness, Anger and Fear: Coping With the Emotions of Illness Hamide Eygoren Register
UPCOMING SESSIONS in ET
Fri, Nov 20, 2026 · 6:00 – 7:00 AM Bangkok
Sadness, Anger and Fear: Coping With the Emotions of Illness
Hamide Eygoren
Register
View all sessions

Long-Term Durability of Acoramidis Efficacy in Transthyretin Amyloid Cardiomyopathy Open-Label Extension of the ATTRibute-CM Randomized Clinical Trial

Source
Jama Cardiology

Key Points

Question  Is long-term treatment with acoramidis in transthyretin amyloid cardiomyopathy associated with sustained clinical benefit through 54 months in the open-label extension of ATTRibute-CM?

Findings  Among 389 participants enrolled in the open-label extension of the ATTRibute-CM randomized clinical trial, early and continuous acoramidis treatment was associated with sustained reductions in all-cause mortality, cardiovascular-related mortality, and first cardiovascular hospitalization, with consistent benefit across prespecified demographic and clinical subgroups. Biomarkers, functional capacity, and health status remained stable or improved, and no new long-term safety concerns were identified.

Meaning  These findings support early and continuous acoramidis treatment to achieve long-term disease stabilization in transthyretin amyloid cardiomyopathy.


[READ MORE]